← Back to Search

Controlled T1D for Type 1 Diabetes

N/A

Waitlist Available

Led By Nicola Santoro, MD, PhD

Research Sponsored by Yale University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be younger than 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline to six hours

Awards & highlights

Study Summary

This trial looks at the difference in how much fat the liver produces in children with poorly controlled type 1 diabetes compared to those who have it under better control, as well as lean controls. They think that those with less controlled diabetes will have higher rates of fat production in the liver.

Eligible Conditions

Type 1 Diabetes
De Novo Lipogenesis

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline to six hours

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline to six hours

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to six hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Fractional hepatic DNL

Trial Design

3Treatment groups

Active Control

Group I: Controlled T1DActive Control1 Intervention

Patients in this group will have T1D and achieve targeted glycemic control (HbA1c <7.5%).

Group II: Lean controlsActive Control1 Intervention

Patients in this group will not have T1D.

Group III: Poorly-controlled T1DActive Control1 Intervention

Patients in this group will have poorly-controlled T1D (HbA1c >8.5%).

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Yale UniversityLead Sponsor

1,847 Previous Clinical Trials

2,737,661 Total Patients Enrolled

Juvenile Diabetes Research FoundationOTHER

232 Previous Clinical Trials

141,777 Total Patients Enrolled

Nicola Santoro, MD, PhDPrincipal InvestigatorAssistant Professor of Pediatrics (Endocrinology)

1 Previous Clinical Trials

260 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are applicants who are older than 45 years of age eligible to enroll in this experiment?

"Eligibility for this trial is restricted to individuals aged between 13 and 22."

Answered by AI

Would I be a viable participant in this research endeavor?

"This research is seeking 30 individuals aged 13 to 22 who have diabetes mellitus. Furthermore, these participants must satisfy the following conditions: a HbA1c level above 8.5% for those with poorly regulated blood glucose levels; and below 7.5% if they are well controlled; at least 12 months of type 1 diabetes (for T1D groups only); and present a negative pregnancy test result (all groups)."

Answered by AI

What is the cap for patient enrollment in this research endeavor?

"Affirmative. The information on clinicaltrials.gov confirms that this experiment is currently seeking volunteers. It was initially uploaded on November 21st 2019 and revised most recently on April 19th 2022, with 30 participants needed at a single site."

Answered by AI

Is this research currently recruiting participants?

"According to the details shared on clinicaltrials.gov, this investigation is actively enrolling participants. It was first made available for public view on November 21st 2019 and underwent its last update in April 19th 2022."

Answered by AI

Recent research and studies

pnpla3Journal

Effect of Gut Microbiota and <i>pnpla3</i> Rs738409 Variant on Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Youth

Monga Kravetz, Ayesha, Todd Testerman, Brittany Galuppo, Joerg Graf, Bridget Pierpont, Stephan Siebel, Richard Feinn, and Nicola Santoro. 2020. “Effect of Gut Microbiota and pnpla3 Rs738409 Variant on Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Youth”. The Journal of Clinical Endocrinology & Metabolism. The Endocrine Society. doi:10.1210/clinem/dgaa382.

clinicaltrials.govStudy

Pathogenesis of the Cardiometabolic Risk in Youth With Type 1 Diabetes

2019. "Pathogenesis of the Cardiometabolic Risk in Youth With Type 1 Diabetes". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04101045.